{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:47:48Z","timestamp":1787503668895,"version":"build-2736575974"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ecl.2025.03.009","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T23:35:53Z","timestamp":1749512153000},"page":"361-375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Advances in Anaplastic Thyroid Cancer Treatment"],"prefix":"10.1016","volume":"54","author":[{"given":"Sarah","family":"Hamidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Maniakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Cabanillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ecl.2025.03.009_bib1","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.clon.2010.03.013","article-title":"Anaplastic thyroid carcinoma: pathogenesis and emerging therapies","volume":"22","author":"Smallridge","year":"2010","journal-title":"Clin Oncol"},{"issue":"11","key":"10.1016\/j.ecl.2025.03.009_bib2","doi-asserted-by":"crossref","DOI":"10.1172\/JCI169653","article-title":"Anaplastic transformation in thyroid cancer revealed by single-cell transcriptomics","volume":"133","author":"Lu","year":"2023","journal-title":"J Clin Investig"},{"issue":"11","key":"10.1016\/j.ecl.2025.03.009_bib3","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1056\/NEJMra1501993","article-title":"Biologic and clinical perspectives on thyroid cancer","volume":"375","author":"Fagin","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ecl.2025.03.009_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14041061","article-title":"Anaplastic thyroid carcinoma: an update","volume":"14","author":"Jannin","year":"2022","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.ecl.2025.03.009_bib5","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1089\/thy.2012.0252","article-title":"Sites of metastases of anaplastic thyroid carcinoma: autopsy findings in 45 cases from a single institution","volume":"23","author":"Besic","year":"2013","journal-title":"Thyroid"},{"issue":"23","key":"10.1016\/j.ecl.2025.03.009_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14235784","article-title":"Prognosis of anaplastic thyroid cancer with distant metastasis","volume":"14","author":"Lee","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ecl.2025.03.009_bib7","article-title":"Impact of somatic mutations on survival outcomes in patients with anaplastic thyroid carcinoma","volume":"6","author":"Wang","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"S1","key":"10.1016\/j.ecl.2025.03.009_bib8","article-title":"Characterization of RAS-mutant anaplastic thyroid carcinoma (ATC)","volume":"34","author":"Sarah Hamidi","year":"2024","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.ecl.2025.03.009_bib9","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J Clin Investig"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.009_bib10","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1089\/thy.2017.0318","article-title":"Gene fusions in thyroid cancer","volume":"28","author":"Yakushina","year":"2018","journal-title":"Thyroid"},{"issue":"4","key":"10.1016\/j.ecl.2025.03.009_bib11","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ecl.2025.03.009_bib12","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/790834","article-title":"Update on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer","volume":"2014","author":"Ragazzi","year":"2014","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.ecl.2025.03.009_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2024.2133","article-title":"Initial management of BRAF V600E-variant anaplastic thyroid cancer: the FAST multidisciplinary group consensus statement","author":"Hamidi","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ecl.2025.03.009_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.971249","article-title":"Effectiveness of core needle biopsy in the diagnosis of thyroid lymphoma and anaplastic thyroid carcinoma: a systematic review and meta-analysis","volume":"13","author":"Vander Poorten","year":"2022","journal-title":"Front Endocrinol"},{"issue":"supplement 2","key":"10.1016\/j.ecl.2025.03.009_bib16","first-page":"337","article-title":"Interest of 18F-FDG PET\/CT in anaplastic thyroid carcinoma","volume":"50","author":"Poisson","year":"2009","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.ecl.2025.03.009_bib17","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1089\/thy.2007.0350","article-title":"18F-FDG PET in the management of patients with anaplastic thyroid carcinoma","volume":"18","author":"Bogsrud","year":"2008","journal-title":"Thyroid\u00ae"},{"key":"10.1016\/j.ecl.2025.03.009_bib18","series-title":"AJCC cancer staging manual","article-title":"Thyroid-differentiated and anaplastic carcinoma (Chapter 73)","author":"Tuttle","year":"2017"},{"issue":"6","key":"10.1016\/j.ecl.2025.03.009_bib19","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/cncy.21992","article-title":"Utility of the BRAF p.V600E immunoperoxidase stain in FNA direct smears and cell block preparations from patients with thyroid carcinoma","volume":"126","author":"Smith","year":"2018","journal-title":"Cancer Cytopathol"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.009_bib20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/thy.2016.0076","article-title":"Real-time genomic characterization utilizing circulating cell-free dna in patients with anaplastic thyroid carcinoma","volume":"27","author":"Sandulache","year":"2017","journal-title":"Thyroid"},{"issue":"8","key":"10.1016\/j.ecl.2025.03.009_bib21","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1089\/thy.2020.0296","article-title":"Clinical utility of circulating Cell-Free DNA mutations in anaplastic thyroid carcinoma","volume":"31","author":"Qin","year":"2021","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.ecl.2025.03.009_bib22","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/thy.2020.0944","article-title":"2021 American thyroid association guidelines for management of patients with anaplastic thyroid cancer","volume":"31","author":"Bible","year":"2021","journal-title":"Thyroid"},{"issue":"5","key":"10.1016\/j.ecl.2025.03.009_bib23","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1089\/thy.2016.0395","article-title":"Patterns of treatment failure in anaplastic thyroid carcinoma","volume":"27","author":"Rao","year":"2017","journal-title":"Thyroid"},{"issue":"12","key":"10.1016\/j.ecl.2025.03.009_bib24","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1210\/jc.2017-01180","article-title":"Survival in response to multimodal therapy in anaplastic thyroid cancer","volume":"102","author":"Prasongsook","year":"2017","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"issue":"S1","key":"10.1016\/j.ecl.2025.03.009_bib25","article-title":"Adjuvant pembrolizumab after multimodal therapy for anaplastic thyroid cancer","volume":"34","author":"Maria","year":"2024","journal-title":"Thyroid"},{"key":"10.1016\/j.ecl.2025.03.009_bib26","doi-asserted-by":"crossref","DOI":"10.1089\/thy.2022.0504","article-title":"Surgery after BRAF-directed therapy is associated with improved survival in BRAF(V600E) mutant anaplastic thyroid cancer: a single-center retrospective cohort study","author":"Zhao","year":"2023","journal-title":"Thyroid"},{"issue":"9","key":"10.1016\/j.ecl.2025.03.009_bib27","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1089\/thy.2019.0514","article-title":"Acquired secondary RAS mutation in BRAF(V600E)-mutated thyroid cancer patients treated with BRAF inhibitors","volume":"30","author":"Cabanillas","year":"2020","journal-title":"Thyroid"},{"issue":"11","key":"10.1016\/j.ecl.2025.03.009_bib28","first-page":"5342","article-title":"The impact of BRAF targeting agents in advanced anaplastic thyroid cancer: a multi-institutional retrospective study in Taiwan","volume":"12","author":"Chang","year":"2022","journal-title":"Am J Cancer Res"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.009_bib29","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1016\/j.clon.2022.10.017","article-title":"Dabrafenib and trametinib therapy for advanced anaplastic thyroid cancer - real-world outcomes from UK Centres","volume":"35","author":"Lorimer","year":"2023","journal-title":"Clin Oncol"},{"key":"10.1016\/j.ecl.2025.03.009_bib30","doi-asserted-by":"crossref","DOI":"10.1089\/thy.2023.0573","article-title":"Checkpoint inhibition in addition to dabrafenib\/trametinib for BRAF(V600E) mutated anaplastic thyroid carcinoma","author":"Hamidi","year":"2024","journal-title":"Thyroid"},{"issue":"11","key":"10.1016\/j.ecl.2025.03.009_bib31","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s00595-022-02494-8","article-title":"Surgical resection of the primary tumor prevents an undesirable locoregional condition and improves the quality of life in patients with anaplastic thyroid cancer","volume":"52","author":"Kanai","year":"2022","journal-title":"Surg Today"},{"issue":"7","key":"10.1016\/j.ecl.2025.03.009_bib32","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1002\/cncr.20936","article-title":"Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors","volume":"103","author":"Kebebew","year":"2005","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.ecl.2025.03.009_bib33","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1089\/thy.2014.0004","article-title":"Early surgery and survival of patients with anaplastic thyroid carcinoma: analysis of a case series referred to a single institution between 1999 and 2012","volume":"24","author":"Brignardello","year":"2014","journal-title":"Thyroid"},{"issue":"20","key":"10.1016\/j.ecl.2025.03.009_bib34","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1200\/JCO.2013.49.6596","article-title":"Remarkable response to crizotinib in woman with anaplastic lymphoma kinase-rearranged anaplastic thyroid carcinoma","volume":"33","author":"Godbert","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ecl.2025.03.009_bib35","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1089\/thy.2019.0477","article-title":"Response to RET-specific therapy in RET fusion-positive anaplastic thyroid carcinoma","volume":"30","author":"Dias-Santagata","year":"2020","journal-title":"Thyroid"},{"issue":"9","key":"10.1016\/j.ecl.2025.03.009_bib36","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ecl.2025.03.009_bib37","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1530\/EJE-21-1259","article-title":"Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma","volume":"186","author":"Waguespack","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"S1","key":"10.1016\/j.ecl.2025.03.009_bib38","article-title":"Fusion-Driven anaplastic thyroid cancer (ATC): characterization and clinical outcomes","volume":"34","author":"Duaa Abdallah","year":"2024","journal-title":"Thyroid"},{"issue":"5","key":"10.1016\/j.ecl.2025.03.009_bib39","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1089\/thy.2012.0598","article-title":"Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer","volume":"24","author":"Blevins","year":"2014","journal-title":"Thyroid"},{"issue":"5","key":"10.1016\/j.ecl.2025.03.009_bib40","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000514182","article-title":"Prevalence and risk factors of developing fistula or organ perforation in patients treated with lenvatinib for radioiodine-refractory thyroid cancer","volume":"10","author":"Valerio","year":"2021","journal-title":"Eur Thyroid J"},{"key":"10.1016\/j.ecl.2025.03.009_bib41","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2022.06.044","article-title":"Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE)","volume":"173","author":"Higashiyama","year":"2022","journal-title":"Eur J Cancer"},{"issue":"21","key":"10.1016\/j.ecl.2025.03.009_bib42","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1200\/JCO.20.03093","article-title":"Open-label, single-arm, multicenter, phase ii trial of lenvatinib for the treatment of patients with anaplastic thyroid cancer","volume":"39","author":"Wirth","year":"2021","journal-title":"J Clin Oncol"},{"issue":"suppl_7","key":"10.1016\/j.ecl.2025.03.009_bib43","article-title":"1646MO - phase II ATLEP trial: Final results for lenvatinib\/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinoma","volume":"33","author":"Dierks","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ecl.2025.03.009_bib44","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3389\/fonc.2019.00106","article-title":"Everolimus in anaplastic thyroid cancer: a case series","volume":"9","author":"Harris","year":"2019","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.ecl.2025.03.009_bib45","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1158\/1078-0432.CCR-17-2297","article-title":"Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase ii study","volume":"24","author":"Hanna","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ecl.2025.03.009_bib46","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2024.4019","article-title":"Dual immune checkpoint inhibition in patients with aggressive thyroid carcinoma: a phase 2 nonrandomized clinical trial","author":"Sehgal","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ecl.2025.03.009_bib47","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2024.4729","article-title":"Anti\u2013programmed death ligand 1 plus targeted therapy in anaplastic thyroid carcinoma: a nonrandomized clinical trial","author":"Cabanillas","year":"2024","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.ecl.2025.03.009_bib48","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ecl.2025.03.009_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201425","article-title":"Efficacy of ALK inhibitors on NSCLC brain metastases: a systematic review and pooled analysis of 21 studies","volume":"13","author":"Petrelli","year":"2018","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ecl.2025.03.009_bib50","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1158\/1535-7163.MCT-18-0695","article-title":"Distribution and activity of lenvatinib in brain tumor models of human anaplastic thyroid cancer cells in severe combined immune deficient mice","volume":"18","author":"Wang","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"10.1016\/j.ecl.2025.03.009_bib51","first-page":"R173","article-title":"Molecular mechanisms of resistance to kinase inhibitors and redifferentiation in thyroid cancers","volume":"29","author":"Hofmann","year":"2022","journal-title":"Endocr Relat Cancer"},{"issue":"7287","key":"10.1016\/j.ecl.2025.03.009_bib52","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"Hatzivassiliou","year":"2010","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.009_bib53","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/s41467-017-01274-0","article-title":"RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition","volume":"8","author":"Jin","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.009_bib54","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00280-023-04544-5","article-title":"Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma","volume":"92","author":"Rasco","year":"2023","journal-title":"Cancer Chemother Pharmacol"},{"issue":"16_suppl","key":"10.1016\/j.ecl.2025.03.009_bib55","doi-asserted-by":"crossref","first-page":"6112","DOI":"10.1200\/JCO.2024.42.16_suppl.6112","article-title":"Safety and efficacy of AIC100 chimeric antigen receptor (CAR) T-cell therapy in patients with advanced thyroid cancers: results from the phase 1 study","volume":"42","author":"Srour","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852925000313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852925000313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T23:01:47Z","timestamp":1753484507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852925000313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0889852925000313"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2025.03.009","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in Anaplastic Thyroid Cancer Treatment","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2025.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}